Faint o gleifion canser a gafodd brawf diagnosteg moleciwlau yn ystod 2015/16 a faint o gleifion oedd yn gymwys i gael profion o'r fath?
Wedi'i ateb gan Ysgrifennydd y Cabinet dros Iechyd, Llesiant a Chwaraeon | Wedi'i ateb ar 15/11/2016
In 2015/16, around 1250 patients received molecular diagnostic testing to predict treatment or confirm diagnosis for colorectal, lung, malignant melanoma and gastrointestinal stromal tumours. In addition, around 560 breast and ovarian cancer patients received testing for the BRCA breast cancer fault genes.
Estimates for the number patients eligible for molecular diagnostic testing are not available.